DanielleElyseAntin-OzerkisMD

Pulmonology • North Haven, CT

Critical Care Medicine

Associate Professor, Internal Medicine, Yale University School of Medicine

Join to view full profile

Dr. Antin-Ozerkis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Antin-Ozerkis' full profile

Already have an account?

Office
6 Devine Street
Yale New Haven Health North Haven Medical Center
North Haven, CT 06473

Education & Training

University of Pennsylvania Health SystemFellowship, Pulmonary Disease and Critical Care Medicine, 2002 - 2006
University of Pennsylvania Health SystemResidency, Internal Medicine, 1999 - 2002
Perelman School of Medicine at the University of PennsylvaniaClass of 1999

Certifications & Licensure

CT State Medical License 2006 - 2025
PA State Medical License 2000 - 2006
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF Start of enrollment: 2009 Oct 01
Completed
Phase 3
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis Start of enrollment: 2009 Oct 01
Terminated
Phase 3
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
Terminated
Phase 2
Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jul 30
Completed
Phase 2
Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis Start of enrollment: 2020 Nov 12
Active, not recruiting
Phase 1, Phase 2
Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2019 Jun 18
Terminated
Phase 3
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2020 Sep 30
Terminated
Phase 3
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis Start of enrollment: 2021 Mar 19
Terminated
Phase 3
A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis Start of enrollment: 2021 Aug 30
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

154 citations
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial
Ganesh Raghu, Bernt van den Blink, Mark J. Hamblin, A. Whitney Brown, Jeffrey A. Golden
JAMA. 2018-06-12
7 citations
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in Peo...
Sindhu R Johnson, Elana J Bernstein, Marcy B Bolster, Jonathan H Chung, Sonye K Danoff
Arthritis & Rheumatology. 2024-08-01
7 citations
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with System...
Sindhu R Johnson, Elana J Bernstein, Marcy B Bolster, Jonathan H Chung, Sonye K Danoff
Arthritis & Rheumatology. 2024-08-01

Press Mentions

2023 ‘Top Doctors’ List Features Over 250 Yale Medicine PhysiciansMay 3rd, 2023
Following Computational Predictions, Scientists Demonstrate That Cancer Drug Counters Pulmonary FibrosisSeptember 1st, 2022
Saracatinib as Effective, or Superior to Ofev, Esbriet in IPF Models: StudyAugust 30th, 2022
Join now to see all